Looks like you’re on the UK site. Choose another location to see content specific to your location
Lilly reports positive clinical data for migraine therapy lasmiditan
Lilly has announced positive new phase III clinical trial data showing the effectiveness of lasmiditan in the acute treatment of migraine.
The oral first-in-class molecule met its primary endpoint in the phase III SPARTAN study, with a greater percentage of patients treated with lasmiditan becoming migraine pain-free at two hours following the first dose when compared to placebo.
These results were statistically significant across all three studied doses – 50 mg, 100 mg and 200 mg – with the drug also meeting its secondary goal by showing its effectiveness in helping to offer relief from patients' most bothersome symptoms.
Findings from the SPARTAN trial were consistent with those of SAMURAI, the first pivotal phase III study evaluating the safety and efficacy of lasmiditan, with results from this trial having been presented earlier this year.
Lilly is hoping to apply for US regulatory approval of the drug during the second half of 2018.
Christi Shaw, president of Lilly Bio-Medicines, said: "We are thrilled with these topline lasmiditan results, which add to more than 25 years of Lilly's research and development of migraine therapies."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard